How to Buy PROCEPT BioRobotics Corporation (PRCT) Shares - Investment in PROCEPT BioRobotics Corporation (PRCT) Stock

Current Stock Performance and Market Position

As of August 25, 2025, PROCEPT BioRobotics Corporation (PRCT) trades at $41.23 on the NASDAQ exchange. The company has demonstrated remarkable resilience and growth momentum despite broader market challenges, making it a compelling story for investors seeking exposure to innovative healthcare technology.

Critical Date Alert: Mark your calendar for October 27, 2025 - this is when PROCEPT will release its Q3 2025 earnings results. Historically, the company's earnings announcements have created significant price movements, offering both opportunities and risks for traders.

Looking back at recent earnings patterns, the August 6, 2025 Q2 report provides valuable insight. The company reported an EPS of -$0.35, beating consensus estimates by $0.06, while revenue surged 48.3% year-over-year to $79.18 million, exceeding analyst expectations of $75.67 million (MarketBeat Earnings Data). This positive surprise triggered immediate market reaction and set the tone for the stock's recent performance.

6-Month Price Journey and Trend Analysis

PROCEPT's stock has experienced significant volatility over the past six months, reflecting both the company's growth trajectory and market sentiment toward emerging medical technology companies:

• February-March 2025: The stock established a foundation around the $50-55 range as investors digested Q4 2024 results and looked toward 2025 guidance.
• April-May 2025: Momentum built as the company demonstrated consistent system placements and recurring revenue growth, pushing prices toward the $60-65 range.
• June-July 2025: Some profit-taking and broader market volatility created a pullback to the $45-50 range, testing investor confidence.
• August 2025: The strong Q2 earnings report on August 6th sparked a recovery, with the stock climbing from approximately $39-40 levels back to current levels around $41.23.

The overall 6-month trend shows a company navigating the challenges of scaling while maintaining strong fundamental growth. Despite some volatility, the underlying business metrics continue to improve dramatically.

Price Forecast: 2025-2030 Outlook

Based on comprehensive analyst projections and the company's execution track record, here's what investors can expect:

• 2025 Year-End Target: $67.94 (average analyst projection) with potential to reach $80.60 if execution exceeds expectations. The current guidance of $325.5 million in revenue for 2025 suggests strong momentum heading into year-end.
• 2026 Outlook: $64.22 represents a conservative one-year projection, though many analysts see potential for higher levels given the company's expansion into prostate cancer treatment and international markets.
• 2028 Projection: While specific 2028 targets aren't explicitly provided, the trajectory suggests potential for $90-110 range based on continued market penetration and new product adoption.
• 2030 Long-term Vision: $121.92 represents the most ambitious long-term target, reflecting the massive addressable market in urological robotics and the company's first-mover advantage in Aquablation therapy.
• Verdict: BUY - The combination of strong revenue growth, expanding margins, and significant market opportunity makes PRCT an attractive investment for those with a medium to long-term horizon.

Risk Assessment for PRCT Investors

Every investment carries risks, and PROCEPT is no exception. Here are the key risk factors to consider:

• Financial Sustainability Risks: The company continues to operate at a loss with negative earnings per share of -$1.51 (Simply Wall St Analysis). While revenue growth is impressive, the path to profitability remains uncertain and requires continued capital investment.
• Market Volatility: With a beta between 0.97-1.12, PRCT exhibits slightly higher volatility than the broader market. The 52-week range of $24.83 to $103.81 demonstrates significant price swings that can test investor patience.
• Regulatory and Reimbursement Challenges: As a medical device company, PROCEPT faces ongoing regulatory scrutiny and dependence on favorable insurance reimbursement policies for its procedures.
• Competitive Landscape: While currently a pioneer in Aquablation therapy, larger medical technology companies could enter the space with competing solutions.
• Execution Risk: Rapid growth requires flawless execution across manufacturing, sales, clinical support, and international expansion - any misstep could impact performance.

Positive Signals and Growth Catalysts

Despite the risks, numerous positive indicators suggest strong potential:

• Explosive Revenue Growth: 48% year-over-year growth in Q2 2025 demonstrates massive market adoption (Q2 2025 Results). The raised guidance to $325.5 million for full-year 2025 confirms this momentum.
• Growing Installed Base: 595 systems installed in the U.S. creates a powerful recurring revenue model from handpieces and consumables.
• Margin Improvement: Gross margins of 64.19% are exceptionally healthy and showing continued improvement (Financial Metrics).
• Market Expansion: International revenue grew 69% in Q2 2025, demonstrating successful global penetration.
• Innovation Pipeline: Expansion into prostate cancer treatment represents a much larger addressable market beyond current BPH focus.

Significant News and Market Impact Analysis

The past six months have been transformative for PROCEPT BioRobotics:

• Q2 2025 Earnings Beat (August 6, 2025): The company exceeded both revenue and EPS expectations, triggering immediate positive price action and renewed investor confidence.
• Leadership Transition Announcement: The appointment of Larry Wood as CEO effective September 2, 2025, brings 40 years of medical technology experience to guide the company's next growth phase.
• Category I CPT Code Assignment: This regulatory milestone improves reimbursement prospects and accessibility for Aquablation therapy, potentially accelerating adoption.
• Clinical Evidence Expansion: Over 150 peer-reviewed publications now support Aquablation therapy, building clinical credibility and driving physician adoption.

Investment Strategy: What Should a Beginner Trader Do Today?

Based on comprehensive analysis, here's my advice for new investors:

1. Start Small but Start Now: Given the volatility, begin with a small position that you can add to during pullbacks. The long-term growth story remains compelling.
2. Dollar-Cost Average: Instead of trying to time the perfect entry, consider regular investments over time to smooth out volatility.
3. Set Price Alerts: Monitor key levels around $35-38 for potential buying opportunities if broader market weakness creates attractive entry points.
4. Focus on Long-Term Horizon: This isn't a quick trade - plan to hold for 2-3 years to capture the full growth story as profitability emerges.
5. Humorous Reality Check: "Trading PRCT is like performing robotic surgery - steady hands and patience yield the best results. Panic selling during volatility is like trying to perform Aquablation therapy with garden hose pressure!"

Step-by-Step Guide to Buying PRCT Shares

Step	Action	Why It Matters
1	Choose a Trading Platform	Select a broker that offers NASDAQ access and competitive commission rates
2	Complete Account Funding	Transfer funds securely; many platforms offer instant deposits for quick trading
3	Search for "PRCT"	Use the exact ticker symbol to find PROCEPT BioRobotics Corporation
4	Review Current Price	Check real-time quotes at $41.23 (as of August 25, 2025) and recent performance
5	Select Order Type	Use limit orders to control entry price rather than market orders
6	Determine Position Size	Calculate based on risk tolerance - typically 2-5% of portfolio for volatile stocks
7	Execute Purchase	Confirm order details including quantity, price, and estimated commission
8	Set Monitoring Alerts	Establish price alerts for earnings dates and key technical levels
9	Document Investment Thesis	Note why you're investing to avoid emotional decisions during volatility
10	Plan Exit Strategy	Determine profit-taking levels and stop-loss parameters before emotions take over

Why Pocket Option Appeals to New Investors

For those beginning their investment journey, Pocket Option offers several advantages that make accessing stocks like PRCT more accessible:

• Minimal Entry Barrier: With a low minimum deposit requirement, new investors can start building positions in promising companies without significant capital commitment.
• Rapid Account Verification: The streamlined KYC process using a single document means you can begin trading quickly when opportunities arise.
• Diverse Withdrawal Options: Multiple funding and withdrawal methods provide flexibility for managing investment capital.
• Educational Resources: The Pocket Option blog offers valuable insights for investors learning to navigate complex markets like medical technology stocks.

Company Overview and Market Position

PROCEPT BioRobotics Corporation stands at the forefront of surgical robotics innovation, specifically focused on urological applications. The company's flagship technology - Aquablation therapy using the HYDROS Robotic System - represents a breakthrough in treating benign prostatic hyperplasia (BPH), a condition affecting approximately 40 million men in the United States alone.

What makes PROCEPT particularly interesting is their first-mover advantage in robotic Aquablation therapy. Unlike traditional surgical approaches, their technology uses ultrasound-guided, heat-free waterjet ablation that's independent of prostate size or surgeon experience. This standardization potential is revolutionizing urological care while creating a scalable business model.

The company's growth strategy revolves around three pillars: expanding their U.S. installed base (currently 595 systems), accelerating international adoption, and developing new applications beyond BPH into prostate cancer treatment. This multi-pronged approach provides multiple growth vectors that reduce single-market dependence.

Interesting Fact from 2025: PROCEPT's technology was featured prominently at the American Urological Association Annual Meeting, where leading physicians demonstrated how their AI-powered robotic system can complete complex prostate procedures in approximately half the time of traditional methods while improving patient outcomes. This clinical validation continues to drive rapid adoption among urologists seeking better solutions for their patients.